Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A M Lincoff

Showing results (71-80 of 116) with videos related to

Pageof 12
Sort By:
Circulation|April 1, 1998
Abciximab therapy and unplanned coronary stent deployment: favorable effects on stent use, clinical outcomes, and bleeding complications. EPILOG Trial InvestigatorsD J Kereiakes, A M Lincoff, D P Miller, et al.
Circulation|June 3, 1998
Diabetes mellitus, glycoprotein IIb/IIIa blockade, and heparin: evidence for a complex interaction in a multicenter trial. EPILOG InvestigatorsN S Kleiman, A M Lincoff, D J Kereiakes, et al.
The American Journal of Cardiology|November 17, 1998
Reduction in the need for unplanned stenting with the use of platelet glycoprotein IIb/IIIa blockade in percutaneous coronary interventionD L Bhatt, A M Lincoff, D J Kereiakes, et al.
Circulation|October 1, 1996
Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteriesW J van der Giessen, A M Lincoff, R S Schwartz, et al.
Circulation|November 15, 1995
Influence of blockade at specific levels of the coagulation cascade on restenosis in a rabbit atherosclerotic femoral artery injury modelY Jang, L A Guzman, A M Lincoff, et al.
Circulation|February 2, 2000
Cost-effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST-elevation acute coronary syndromesD B Mark, R A Harrington, A M Lincoff, et al.
Circulation|December 22, 1999
Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: results of the EPISTENT (Evaluation of platelet IIb/IIIa inhibitor for stenting trial) diabetic substudyS P Marso, A M Lincoff, S G Ellis, et al.
American Heart Journal|January 5, 2000
The PRESTO (Prevention of restenosis with tranilast and its outcomes) protocol: a double-blind, placebo-controlled trialD Holmes, P Fitzgerald, S Goldberg, et al.
The American Journal of Cardiology|July 22, 1998
Platelet glycoprotein IIb/IIIa receptor blockade with abciximab reduces ischemic complications in patients undergoing directional coronary atherectomy. EPILOG Investigators. Evaluation of PTCA to Improve Long-term Outcome by c7E3 GP IIb/IIIa Receptor BlockadeS Ghaffari, D J Kereiakes, A M Lincoff, et al.
Circulation|December 22, 1998
Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart diseaseD F Kong, R M Califf, D P Miller, et al.
Pageof 12

Showing results (71-80 of 116) with videos related to

Sort By:
Pageof 12
Circulation|April 1, 1998
Abciximab therapy and unplanned coronary stent deployment: favorable effects on stent use, clinical outcomes, and bleeding complications. EPILOG Trial InvestigatorsD J Kereiakes, A M Lincoff, D P Miller, et al.
Circulation|June 3, 1998
Diabetes mellitus, glycoprotein IIb/IIIa blockade, and heparin: evidence for a complex interaction in a multicenter trial. EPILOG InvestigatorsN S Kleiman, A M Lincoff, D J Kereiakes, et al.
The American Journal of Cardiology|November 17, 1998
Reduction in the need for unplanned stenting with the use of platelet glycoprotein IIb/IIIa blockade in percutaneous coronary interventionD L Bhatt, A M Lincoff, D J Kereiakes, et al.
Circulation|October 1, 1996
Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteriesW J van der Giessen, A M Lincoff, R S Schwartz, et al.
Circulation|November 15, 1995
Influence of blockade at specific levels of the coagulation cascade on restenosis in a rabbit atherosclerotic femoral artery injury modelY Jang, L A Guzman, A M Lincoff, et al.
Circulation|February 2, 2000
Cost-effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST-elevation acute coronary syndromesD B Mark, R A Harrington, A M Lincoff, et al.
Circulation|December 22, 1999
Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: results of the EPISTENT (Evaluation of platelet IIb/IIIa inhibitor for stenting trial) diabetic substudyS P Marso, A M Lincoff, S G Ellis, et al.
American Heart Journal|January 5, 2000
The PRESTO (Prevention of restenosis with tranilast and its outcomes) protocol: a double-blind, placebo-controlled trialD Holmes, P Fitzgerald, S Goldberg, et al.
The American Journal of Cardiology|July 22, 1998
Platelet glycoprotein IIb/IIIa receptor blockade with abciximab reduces ischemic complications in patients undergoing directional coronary atherectomy. EPILOG Investigators. Evaluation of PTCA to Improve Long-term Outcome by c7E3 GP IIb/IIIa Receptor BlockadeS Ghaffari, D J Kereiakes, A M Lincoff, et al.
Circulation|December 22, 1998
Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart diseaseD F Kong, R M Califf, D P Miller, et al.
Pageof 12